[参考文献]

[1] Plemons Jm，alhashimi I ，Marek CL， et al.managing xerostomia and salivary gland hypofunction: executive summary of a report from the American Dental Association Council on Scientific Affairs[j].j Am Dent Assoc, 2014, 145: 867-873. [ 2 ] Me i j e r J M， Me i n e r s P M， Vi s s i n k A , e t al.effectiveness of rituximab treatment in primary Sjogren's syndrome:a randomized，double-blind，placebo-controlled trial[j].arthritis Rheum,2010，62:960-968. [ 3] Foulks GN, Forstot SL, Donshik PC, et al. Clinical guidelines for management of dry eye associated with sjogren's disease[j]. Ocul Surf,2015, 13: 118-132. [4] Gottenberg J E, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial[ J]. JAMA, 2014, 312: 249-258. [ 5] Jager D J, Karagozoglu KH, Maarse F, et al. Sialendoscopy of salivary glands affected by sjogren's syndrome: a randomized controlled pilot study[ J]. J Oral Maxillofac Surg,2016,74:1167-1174. [6] Fauchais A L,ouattara B,gondran G,et al.articular manifestations in primary sjogren's syndrome: clinical significance and prognosis of 188 patients[j].rheumatology( Oxford),2010,49:1164-1172. [ 7] Kuhn A, Sigges J, Biazar C, et al. Influence of s moking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database[ J]. Br J Dermatol,2014,171:571-579. [8] King TE Jr,bradford Wz,castro-bernardini S,et al.a phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis[j].n Engl J Med,2014,370:2083-2092. [9] Evans Rd,laing Cm,ciurtin C,et al. Tubulointerstitial nephritis in primary sjogren's syndrome:clinical manifestations and response to treatment[j].bmc Musculoskelet Disord,2016,17:2. [10] Saraux A,pers Jo,devauchelle-pensec V. Treatment of primary sjogren's syndrome[ J]. Nat Rev Rheumatol,2016,12:456-471. [11] Colafrancesco S,priori R,gattamelata A,et al.myositis in primary sjogren's syndrome: data from a multicentre cohort[ J]. Clin Exp Rheumatol,2015,33:457-464. [ 12] Rist S, Sellam J, Hachulla, et al. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary sjogren's syndrome:a national multicentric retrospective study[j].arthritis Care Res,2011,63:13391344. [ 13] Flanagan E P, Weinshenker BG, Krecke KN, et al. Short myelitis lesions in aquaporin‑4‑igg- positive neuromyelitis optica s p e c t r u m d i s o r d e r s [ J ] . J AMA Neurol,2015,72:81-87. [14] Visentini M,tinelli C,colantuono S,et al.efficacy of low- dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: phase II clinical trial and systematic review[j]. Autoimmun Rev,2015,14:889-896. [ 1 5 ] C h e n H , Z h e n g W, S u J , e t a l . L o w - d o s e rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus--a prospective pilot study[j].rheumatology (Oxford),2011,50:1640-1644. [16] Mealy M A，wingerchuk D M，palace J，et al.comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy[j].jama Neurol,2014,71:324-330. [17] Carsons Se，vivino Fb,parke A，et al.treatment guidelines for rheumatologic manifestations of sjogren's syndrome:use of biologic agents,management of fatigue， and inflammatory musculoskeletal pain[j].arthritis Care Res， 2016 Jul 7.doi:10.1002/acr.22968. [ 18] Vivino FB， Carsons SE， Foulks G, et al. New treatment guidelines for Sjögren’s disease[j].rheum Dis Clin North Am,2016,42:531-551.

（摘自《中国实用内科杂志》） （编辑 凤池）